Results 151 to 160 of about 51,251 (187)

Real-World Comparative Efficacy and Safety of Upadacitinib, Tofacitinib, and Filgotinib in Patients With Ulcerative Colitis. [PDF]

Cureus
Ahmad F, Hussain T, Gunaratne CH, Collum J, Ghaffar A, Gharbia K.   +5 more
europepmc   +1 more source

Valore predittivo di variabili clinico-laboratoristiche in pazienti con mielofibrosi trattati con inibitore di JAK-1/2 [PDF]

, 2011
CARAMAZZA, Domenica
core  

JAK Inhibitors and Memory Impairment: Disproportionality Analyses in the WHO Global Pharmacovigilance Database, VigiBase. [PDF]

Fundam Clin Pharmacol
Duboëlle M, Lercara A, Pers YM, Michel C, Lepelley M, Valnet-Rabier MB, Faillie JL, Bres V, Palassin P.   +8 more
europepmc   +1 more source

Emerging role of Janus kinase inhibitors in ulcerative colitis management. [PDF]

World J Gastrointest Pharmacol Ther
Ahsan MU, Sajid SL, Balach R, Daniyal M, Ain NU, Mudasir M.   +5 more
europepmc   +1 more source

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis. [PDF]

Cureus
Burashed KK, AlAbbasi FA.
europepmc   +1 more source

Beyond a gatekeeper: the non-classical signaling role of STRA6 in driving endothelial senescence and atherosclerosis. [PDF]

Front Immunol
Yuan Y, Wang J, Zhang Y, Yu Y, Shi W, Chen S, Kuang Y, Feng L.   +7 more
europepmc   +1 more source

Clinical updates of JAK inhibitors in cutaneous granulomatous diseases. [PDF]

Front Immunol
Gu J, He X, Lu B, Wang J, Chen K, Wang Q, Jian X, Huang C, Yu B.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Investigational Janus kinase inhibitors

Expert Opinion on Investigational Drugs, 2013
Dysregulation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is central to the pathophysiology of myeloproliferative neoplasms (MPN). Small molecule inhibitors of JAK family members are currently under investigation for the treatment of MPN.
Constantine S, Tam, Srdan, Verstovsek
openaire   +2 more sources

Janus-Kinase-Hemmer

Zeitschrift für Rheumatologie, 2012
Die Janus-Kinase-Inhibitoren stellen einen neuen therapeutischen Ansatz in der Behandlung der rheumatoiden Arthritis dar. In Phase-II- und -III-Studien zu Tofacitinib zeigte sich eine gute klinische Wirksamkeit mit einem ACR (American College of Rheumatology)-20-Ansprechen von > 50% sowohl fur die Mono- als auch die Kombinationstherapie mit Methotrexat.
E. Ostermeier, P. Roll, H.-P. Tony
openaire   +1 more source